Antares Pharma, Inc (ATRS)

Etorro trading 970x250

About Antares Pharma, Inc

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company’s injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and for glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto injectors; and drug/device product for urologic oncology and endocrinology. The company have strategic alliances and partnership arrangements pharmaceutical companies, including Pfizer, Idorsia, Teva, and AMAG. Antares Pharma, Inc. was founded in 1978 and is headquartered in Ewing, New Jersey. Address: 100 Princeton South, Ewing, NJ, United States, 08628

Antares Pharma, Inc News and around…

Latest news about Antares Pharma, Inc (ATRS) common stock and company :

Antares Pharma Enters into Exclusive License Agreement With Lipocine for TLANDO® in U.S.
18 Oct, 2021 Yahoo! Finance

Expands Proprietary Portfolio and Complements Testosterone Offering to Physicians and PatientsEWING, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that it entered into an exclusive license agreement with Lipocine Inc. (“Lipocine”), a clinical-stage biopharmaceutical company, for TLANDO® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”) in the United States (

Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
30 Sep, 2021 FinancialContent

Pharmacokinetic data results expected in 1Q 2022

5 Value Stocks To Watch In The Healthcare Sector
27 Sep, 2021 FinancialContent

The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same ...

Analysts See 18% Gains Ahead For SMLF
22 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Small-Cap Multifactor ETF (SMLF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $63.71 per unit.

Investing in Antares Pharma (NASDAQ:ATRS) five years ago would have delivered you a 122% gain
21 Sep, 2021 Yahoo! Finance

Antares Pharma, Inc. ( NASDAQ:ATRS ) shareholders might be concerned after seeing the share price drop 16% in the last...

Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
08 Sep, 2021 FinancialContent
Got $1,000? These 2 Bargain-Bin Biopharma Stocks Might Be Worth Buying
27 Aug, 2021 FinancialContent

These healthcare stocks have their warts, but the price is right for long-term investors.

Is Antares Pharma (NASDAQ:ATRS) A Risky Investment?
16 Aug, 2021 Yahoo! Finance

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Antares Pharma Reports Second Quarter 2021 Financial and Operating Results
05 Aug, 2021 FinancialContent
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
01 Aug, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week endingJuly 30 amid earnings releases from big pharma companies. Most ...

Were Hedge Funds Right About Antares Pharma Inc (ATRS)?
29 Jul, 2021 Yahoo! Finance

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

Antares Pharma (ATRS) Earnings Expected to Grow: Should You Buy?
29 Jul, 2021 Yahoo! Finance

Antares Pharma (ATRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Antares Pharma to Report Second Quarter 2021 Financial and Operating Results
28 Jul, 2021 FinancialContent
Antares To Start Testing ATRS-1902 With Injector Technology In Patients With Adrenal Crisis
22 Jul, 2021 FinancialContent

TheFDA has acceptedAntares Pharma Inc's(NASDAQ: ATRS) Investigational New Drug Application (IND) for ATRS-1902 ...

Antares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for Adrenal Crisis Rescue
22 Jul, 2021 FinancialContent
Sum Up The Parts: IHE Could Be Worth $221
20 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares US.

Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021
16 Jul, 2021 FinancialContent

Upgrades According to Citigroup, the prior rating for Alcoa Corp (NYSE:AA) was changed from Neutral to Buy. In the ...

Is Antares Pharma, Inc.'s (NASDAQ:ATRS) Stock's Recent Performance A Reflection Of Its Financial Health?
11 Jul, 2021 Yahoo! Finance

Antares Pharma's (NASDAQ:ATRS) stock up by 8.0% over the past three months. Since the market usually pay for a...

Antares Pharma to Present at the Ladenburg Thalmann Annual Healthcare Conference
07 Jul, 2021 FinancialContent
7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
05 Jul, 2021 FinancialContent
Antares Pharma Announces Partner Idorsia Initiates the Phase 3 Study With Selatogrel for Acute Myocardial Infarction
28 Jun, 2021 FinancialContent
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
28 Jun, 2021 FinancialContent
Antares Pharma Announces Submission of IND Application for ATRS-1902 for Adrenal Crisis Rescue
22 Jun, 2021 FinancialContent
Antares Pharma to Present at the Raymond James Human Health Innovations Conference
15 Jun, 2021 FinancialContent
Shareholders May Not Be So Generous With Antares Pharma, Inc.'s (NASDAQ:ATRS) CEO Compensation And Here's Why
05 Jun, 2021 Yahoo! Finance

CEO Bob Apple has done a decent job of delivering relatively good performance at Antares Pharma, Inc. ( NASDAQ:ATRS...

Here's Why We Think Antares Pharma (NASDAQ:ATRS) Is Well Worth Watching
01 Jun, 2021 Yahoo! Finance

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...

Antares Pharma to Present at the Jefferies Virtual Healthcare Conference
26 May, 2021 FinancialContent
Look Under The Hood: XHE Has 26% Upside
13 May, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $144.66 per unit.

Antares Pharma (ATRS) Meets Q1 Earnings Estimates
06 May, 2021 Yahoo! Finance

Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 2.98%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Antares Pharma, Inc (ATRS) is a NASDAQ Common Stock listed in , ,

970x250